Ondine CEO increases ownership
CEO and husband purchase 100,000 shares at 12.5p, increasing combined stake to 35.33%.
- Shares purchased 100,000
- Price per share 12.5 pence
- Combined ownership stake 35.3284%
Select text to share a quote on X · sign in to keep highlights & notes in your OBI notes
Ondine Biomedical Inc. (AIM: OBI), a Canadian life sciences company pioneering light-activated antimicrobial treatments, announces that The Pennycook Family Trust, controlled by Carolyn Cross, CEO, and Robert Cross, husband of Carolyn Cross, has purchased 100,000 shares ("Common Shares") in the Company at a price of 12.5 pence per Common Share on 31 January 2025.
Following this transaction, Carolyn Cross and Robert Cross, directly and indirectly, hold 156,164,804 Common Shares representing 35.3284%% of the issued share capital of the Company.
About Ondine Biomedical Inc.
| 1. | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Carolyn Cross and her PCA |
| 2. | Reason for the Notification | |
| a) | Position/status | Chief Executive Officer (PDMR) |
| b) | Initial notification/Amendment | Initial notification |
| a) | Name | Ondine Biomedical Inc. |
| b) | LEI | 9845005B69E07CGF4A56 |
| a) | Description of the Financial instrument, type of instrument | Common shares |
| Identification code | ISIN: CA68234M2058 | |
| b) | Nature of the transaction | Share purchase |
| c) | Price(s) and volume(s) | 100,000 shares at 12.5 pence each |
| d) | Aggregated information: ·Aggregated volume ·Price | N/A |
| e) | Date of the transaction | 31 January 2025 |
| f) | Place of the transaction | AIM |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.